Seven Mile Advisory’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$404K Buy
2,129
+18
+0.9% +$3.39K 0.27% 77
2026
Q1
$416K Buy
2,111
+7
+0.3% +$1.35K 0.3% 70
2025
Q4
$387K Sell
2,104
-344
-14% -$60.3K 0.07% 140
2025
Q3
$376K Buy
2,448
+252
+11% +$38.1K 0.06% 170
2025
Q2
$307K Sell
2,196
-84
-4% -$11.8K 0.18% 116
2025
Q1
$335K Buy
2,280
+227
+11% +$32.8K 0.22% 97
2024
Q4
$269K Sell
2,053
-33
-2% -$4.62K 0.17% 113
2024
Q3
$325K Buy
2,086
+375
+22% +$60.5K 0.22% 93
2024
Q2
$267K Buy
1,711
+189
+12% +$28.4K 0.2% 107
2024
Q1
$206K Buy
+1,522
New +$202K 0.16% 148
2023
Q4
Sell
-1,833
Closed -$248K 152
2023
Q3
$248K Buy
1,833
+109
+6% +$14.9K 0.26% 91
2023
Q2
$247K Buy
+1,724
New +$254K 0.29% 84

Other funds holding AZN

Seven Mile Advisory's AZN Position: Q2 2026 in Review

Seven Mile Advisory increased its AstraZeneca (AZN) stake by 0.85% in Q2 2026, buying an estimated $3.39K and bringing the position to 2,129 shares worth $404K. The position accounts for 0.27% of the portfolio, ranked #77.

Seven Mile Advisory first reported a position in AZN in Q2 2023 and has held it in 12 quarters since. The position peaked at $416K in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Seven Mile Advisory held 2,129 shares of AstraZeneca worth $404K as of Q2 2026.
  • Seven Mile Advisory bought 18 AstraZeneca shares in Q2 2026, an estimated $3.39K.
  • AstraZeneca made up 0.27% of Seven Mile Advisory's portfolio in Q2 2026, its #77 holding.
  • Seven Mile Advisory first reported a position in AstraZeneca in Q2 2023 and has held it in 12 quarters since.
  • Seven Mile Advisory's AstraZeneca position peaked at $416K in Q1 2026.
  • 1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Seven Mile Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.